Early detection remains the primary way to prevent the development of life-threatening cancer. However, early diagnosis in most types of cancer remains challenging due to the lack of symptoms in the early stage or to the fact that current screening approaches are not sensitive or specific enough.
Isolation of these cells, a cancer-derived biomarker, from peripheral blood allowing their genomic and proteomic assessment represents an extraordinarily diagnostic tool called ‘liquid biopsy”.
Its potential applications are rapidly growing: from cancer early diagnostic, genomic profiling to the monitoring of tumor eradication after curative surgery, from evaluating either response or resistance to systemic treatments to quantifying minimal residual disease.
by becoming the new paradigm in healthcare as it enables better resources allocation, treatment optimization with a potential side-effect’s reduction and consequent impact on quality of life and survival. This revolution is being catalyzed by liquid biopsy technologies, which provide prognostic and predictive information for cancer patients.
Tumor genetics and proteomics are continuously evolving in a relatively short period of time. Drug’s efficacy strongly depends on these changes: thus, longitudinal monitoring can provide important information for the best therapy strategy.
Tethis’ diagnostic platform rapidly intercepts those changes with a non-invasive and biologically exhaustive approach to help oncologists in their daily decisions.
Lorem ipsum dolor sit amet, consectetur adipisci elit, sed eiusmod tempor incidunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur.
Lorem ipsum dolor sit amet, consectetur adipisci elit, sed eiusmod tempor incidunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur.
Lorem ipsum dolor sit amet.
